ARCH Venture Fund VII, L.P.

ARCH Venture Fund VII, L.P. has filed trades across 7 companies (mainly through SEC (Form 4)), most often in Syros Pharmaceuticals, Inc., Receptos, Inc. and Sage Therapeutics, Inc. In total, 40 filings cover trades dated from 14 May 2013 to 22 December 2020.

Both buying and selling appear: 3 purchases worth €12.5M, against 16 sales worth €3.6M. On balance, insiders were net buyers of €8.9M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. So far in 2020, the count stands at 1 purchase and no sales.

Half of the purchases are above €4.5M and half below.

On 22 December 2020 came the latest disclosure, a transaction in 908 Devices Inc. The latest purchase dates back some time: it was published 2,148 days ago, on 22 December 2020. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.